DRMA vs. SLRX, CNSP, CWBR, SXTP, SNOA, GLMD, BPTH, NTBL, CMND, and ATXI
Should you be buying Dermata Therapeutics stock or one of its competitors? The main competitors of Dermata Therapeutics include Salarius Pharmaceuticals (SLRX), CNS Pharmaceuticals (CNSP), CohBar (CWBR), 60 Degrees Pharmaceuticals (SXTP), Sonoma Pharmaceuticals (SNOA), Galmed Pharmaceuticals (GLMD), Bio-Path (BPTH), Notable Labs (NTBL), Clearmind Medicine (CMND), and Avenue Therapeutics (ATXI). These companies are all part of the "pharmaceutical preparations" industry.
Dermata Therapeutics (NASDAQ:DRMA) and Salarius Pharmaceuticals (NASDAQ:SLRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, analyst recommendations, media sentiment, community ranking, dividends and earnings.
8.7% of Dermata Therapeutics shares are owned by institutional investors. Comparatively, 11.9% of Salarius Pharmaceuticals shares are owned by institutional investors. 4.3% of Dermata Therapeutics shares are owned by insiders. Comparatively, 3.5% of Salarius Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Dermata Therapeutics has higher earnings, but lower revenue than Salarius Pharmaceuticals. Salarius Pharmaceuticals is trading at a lower price-to-earnings ratio than Dermata Therapeutics, indicating that it is currently the more affordable of the two stocks.
Salarius Pharmaceuticals received 22 more outperform votes than Dermata Therapeutics when rated by MarketBeat users. Likewise, 54.17% of users gave Salarius Pharmaceuticals an outperform vote while only 44.44% of users gave Dermata Therapeutics an outperform vote.
In the previous week, Salarius Pharmaceuticals had 3 more articles in the media than Dermata Therapeutics. MarketBeat recorded 4 mentions for Salarius Pharmaceuticals and 1 mentions for Dermata Therapeutics. Dermata Therapeutics' average media sentiment score of 1.89 beat Salarius Pharmaceuticals' score of 1.12 indicating that Dermata Therapeutics is being referred to more favorably in the media.
Dermata Therapeutics' return on equity of -107.95% beat Salarius Pharmaceuticals' return on equity.
Dermata Therapeutics has a beta of 0.89, meaning that its stock price is 11% less volatile than the S&P 500. Comparatively, Salarius Pharmaceuticals has a beta of 0.95, meaning that its stock price is 5% less volatile than the S&P 500.
Summary
Dermata Therapeutics beats Salarius Pharmaceuticals on 7 of the 13 factors compared between the two stocks.
Get Dermata Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for DRMA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DRMA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Dermata Therapeutics Competitors List
Related Companies and Tools
